The impressive effects of other antiangiogenics with high affinity against VEGFR2 such as lenvatinib (in gastric [34] and endometrial cancer [35]) or axitinib (in kidney cancer [36]) in combination with pembrolizumab should make at least consider these partners in for combination with immunotherapy in future trials in breast cancer exploring this concept. This evidence concerns the gene KDR and breast cancer.